Bigmurph6
Banned
Steranabol Ritardo (oxabolone cypionate)
Androgenic 20-60
Anabolic 50-90
Chemical Names
19-norandrost-4-en-4,17b-ol-3-one
4,17beta-dihydroxyestr-4-en-3-one
Estrogenic Activity none
Progestational Activity none
Description
Oxabolone cypionate is an injectable anabolic steroid that is a close structural derivative of 19-nortestosterone (nandrolone). The base steroid differs from nandrolone only by the addition of a 4-hydroxyl group, the same alteration that is used to make hydroxytestosterone from testosterone.
As nandrolone-based compound,
oxabolone is more anabolic than androgenic in nature, although it is comparably more androgenic than its parent due to differences in metabolism. Oxabolone is also non-aromatizable, and less likely to produce estrogenic side effects. In terms of muscle-building potency, oxabolone is weaker than nandrolone, but it seems to produce an even harder, tighter look in comparison, probably owing to the fact that it does not have the same low level of estrogenic during cutting/hardening cycles, or prefer purer strength nandrolone derivative is often a valuable find.
activity. For those who find nandrolone to be a failure and lean muscle gains without water/fat retention, this nandrolone derivative is often a valuable find.
History
Oxabolone was first described in 1934.1 It was finally developed into a long-acting injectable medication during the 1960’s, sold by Farmitalia Carlo Erba in Italy and Germany as Steranabol-Ritardo and Steranabol-Depot, respectively. This relatively mild nandrolone derivative was used mainly to treat osteoporosis, although it has also been indicated when there was a need for a protein-sparing anabolic agent. It appears to have exhibited a very favorable clinical record, having been used effectively in men, women, the elderly, and children with minimal side effects for several decades. By all accounts, the drug was very safe. There is a great lack of information on this agent in the medical literature, however, being that it was used in a small number of markets only. As such, there is much less data to draw from than with many of the more widely used compounds.
Pharmacia acquired Farmitalia in 1993, at the time one of the largest pharmaceutical conglomerates in the world.
Two years later, Pharmacia would go on to merge with Upjohn, another long-standing giant in the drug business The Steranabol-Depot brand from Germany had been discontinued years earlier, but the Italian product remained on the market well after this corporate transition. For several years it was sold in Italy as a Pharmacia & Upjohn product. Steranabol Ritardo too was eventually discontinued, however, and would be gone by the time Pfizer acquired Pharmacia in 2003. The drug has been out of commerce for long enough now that it has been effectively removed from the black market. The dosage of this product was considerably low anyway (12.5 mg/ml), and as such was never very popular among athletes. Since this was the last remaining prescription drug product to contain oxabolone cypionate worldwide, this marked the commercial end to this steroid. Note that although this agent was unknown to U.S. Federal lawmakers before, it was added to the Anabolic Steroid Control Act in 2005.
Androgenic 20-60
Anabolic 50-90
Chemical Names
19-norandrost-4-en-4,17b-ol-3-one
4,17beta-dihydroxyestr-4-en-3-one
Estrogenic Activity none
Progestational Activity none
Description
Oxabolone cypionate is an injectable anabolic steroid that is a close structural derivative of 19-nortestosterone (nandrolone). The base steroid differs from nandrolone only by the addition of a 4-hydroxyl group, the same alteration that is used to make hydroxytestosterone from testosterone.
As nandrolone-based compound,
oxabolone is more anabolic than androgenic in nature, although it is comparably more androgenic than its parent due to differences in metabolism. Oxabolone is also non-aromatizable, and less likely to produce estrogenic side effects. In terms of muscle-building potency, oxabolone is weaker than nandrolone, but it seems to produce an even harder, tighter look in comparison, probably owing to the fact that it does not have the same low level of estrogenic during cutting/hardening cycles, or prefer purer strength nandrolone derivative is often a valuable find.
activity. For those who find nandrolone to be a failure and lean muscle gains without water/fat retention, this nandrolone derivative is often a valuable find.
History
Oxabolone was first described in 1934.1 It was finally developed into a long-acting injectable medication during the 1960’s, sold by Farmitalia Carlo Erba in Italy and Germany as Steranabol-Ritardo and Steranabol-Depot, respectively. This relatively mild nandrolone derivative was used mainly to treat osteoporosis, although it has also been indicated when there was a need for a protein-sparing anabolic agent. It appears to have exhibited a very favorable clinical record, having been used effectively in men, women, the elderly, and children with minimal side effects for several decades. By all accounts, the drug was very safe. There is a great lack of information on this agent in the medical literature, however, being that it was used in a small number of markets only. As such, there is much less data to draw from than with many of the more widely used compounds.
Pharmacia acquired Farmitalia in 1993, at the time one of the largest pharmaceutical conglomerates in the world.
Two years later, Pharmacia would go on to merge with Upjohn, another long-standing giant in the drug business The Steranabol-Depot brand from Germany had been discontinued years earlier, but the Italian product remained on the market well after this corporate transition. For several years it was sold in Italy as a Pharmacia & Upjohn product. Steranabol Ritardo too was eventually discontinued, however, and would be gone by the time Pfizer acquired Pharmacia in 2003. The drug has been out of commerce for long enough now that it has been effectively removed from the black market. The dosage of this product was considerably low anyway (12.5 mg/ml), and as such was never very popular among athletes. Since this was the last remaining prescription drug product to contain oxabolone cypionate worldwide, this marked the commercial end to this steroid. Note that although this agent was unknown to U.S. Federal lawmakers before, it was added to the Anabolic Steroid Control Act in 2005.
